Barclays’s Turnstone Biologics TSBX Stock Holding History

Barclays’s Portfolio TSBX Stock Details TSBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-114,058	Closed	-$56.7K	–	5557
2024 Q4	$56.7K	Buy	114,058 +4,014	+4%	+$1.98K	﹤0.01%	4733
2024 Q3	$61.3K	Sell	110,044 -5,934	-5%	-$9.11K	﹤0.01%	4701
2024 Q2	$304K	Sell	115,978 -5,403	-4%	-$15.4K	﹤0.01%	3339
2024 Q1	$318K	Buy	121,381 +5,265	+5%	+$15.1K	﹤0.01%	3858
2023 Q4	$296K	Buy	+116,116	New	+$303K	﹤0.01%	4219

Other funds holding TSBX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays's TSBX Position: Q1 2025 in Review

Barclays sold out of Turnstone Biologics (TSBX) in Q1 2025, closing a stake of 114,058 shares — an estimated $56.7K sold.

Barclays first reported a position in TSBX in Q4 2023 and held it in 5 quarters. The position peaked at $318K in Q1 2024. 23 funds tracked by Wall St. Rank hold TSBX as of Q1 2025.

Barclays reported no remaining Turnstone Biologics position as of Q1 2025 after selling out during the quarter.
Barclays sold 114,058 Turnstone Biologics shares in Q1 2025, an estimated $56.7K.
Barclays first reported a position in Turnstone Biologics in Q4 2023 and held it in 5 quarters.
Barclays's Turnstone Biologics position peaked at $318K in Q1 2024.
23 funds tracked by Wall St. Rank held Turnstone Biologics as of Q1 2025.

Based on Barclays's 13F filing for Q1 2025, filed 15 May 2025.